Abstract
Glycolipids are amphipathic molecules which are highly expressed on cell membranes in skin and brain where they mediate several key cellular processes. Neural stem cells are defined as undifferentiated, proliferative, multipotential cells with extensive self-renewal and are responsive to brain injury. Di-rhamnolipid: α-l-rhamnopyranosyl-(1-2)α-l-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid, also referred to as di-rhamnolipid BAC-3, is a glycolipid isolated from the bacteria Pseudomonas aeruginosa. In the previous studies, di-rhamnolipid enhanced dermal tissue healing and regeneration. The present study provides the first assessment of di-rhamnolipid, and glycolipid biosurfactants in general, on the nervous system. Treatment of neural stem cells isolated from the lateral ventricle of adult mice and cultured in defined media containing growth factors at 0.5 and 1 μg/ml of di-rhamnolipid increased the number of neurospheres (2.7- and 2.8-fold, respectively) compared to controls and this effect remained even after passaging in the absence of di-rhamnolipid. In addition, neural stem cells treated with di-rhamnolipid at 50 and 100 μg/ml in defined media supplemented with fetal calf serum and without growth factors exhibited increased cell viability, indicating an interaction between di-rhamnolipid and serum components in the regulation of neural stem cells and neuroprogenitors. Intracerebroventricular administration of di-rhamnolipid at 300 and 120 ng/day increased the number of neurospheres (1.3- and 1.63-fold, respectively) that could be derived from the anterior lateral ventricles of adult mice. These results indicate that di-rhamnolipid stimulates proliferation of neural stem cells and increases their endogenous pools which may have therapeutic potential in managing neurodegenerative or neuropsychiatric disorders and promoting nervous tissue regeneration following injury.
Similar content being viewed by others
References
Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Paterson AC, Reynolds BA (1996) Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci 16:7599–7609
Ikami T, Ishida H, Kiso M (2000) Synthesis and biological activity of glycolipids, with a focus on gangliosides and sulfatide analogs. Methods Enzymol 311:547–568
Miyakoshi LM, Todeschini AR, Mendez-Otero R, Hedin-Pereira C (2012) Role of the 9-O-acetyl GD3 in subventricular zone neuroblast migration. Mol Cell Neurosci 49:240–249
Yanagisawa M, Taga T, Nakamura K, Ariga T, Yu RK (2005) Characterization of glycoconjugate antigens in mouse embryonic neural precursor cells. J Neurochem 95:1311–1320
Fantini J, Barrantes FJ (2009) Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta 1788:2345–2361
Yu RK, Yanagisawa M (2007) Glycosignaling in neural stem cells: involvement of glycoconjugates in signal transduction modulating the neural stem cell fate. J Neurochem 103:39–46
Wennekes T, van den Berg RJBHN, Boot RG, van der Marel GA, Overkleeft HS, Aerts JMFG (2009) Glycosphingolipids—nature, function, and pharmacological modulation. Angew Chem Int Ed 48:8848–8869
Yu RK, Nakatani Y, Yanagisawa M (2009) The role of glycosphingolipid metabolism in the developing brain. J Lipid Res 50:440–445
Ariga T, McDonald MP, Yu RK (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease-a review. J Lipid Res 49:1157–1175
Kornhuber J, Reichel M, Tripal P, Groemer TW, Henkel AW, Mühle C, Gulbins E (2009) The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 259:199–204
Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA (2009) Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 87:278–288
Valdomero A, Hansen C, de Burgos NG, Cuadra GR, Orsingher OA (2010) GM1 ganglioside enhances the rewarding properties of cocaine in rats. Eur J Pharmacol 630:79–83
Jarvis FG, Johnson MJ (1949) A glyco-lipid produced by Pseudomonas aeruginosa. J Am Chem Soc 71:4124–4126
Maier RM, Soberon-Chavez G (2000) Pseudomonas aeruginosa rhamnolipids: biosynthesis and potential applications. Appl Microbiol Biotechnol 54:625–633
Rodrigues L, Banat IM, Teixeira J, Oliveira R (2006) Biosurfactants: potential applications in medicine. J Antimicrob Chemother 57:609–618
Stipcevic T, Piljac T, Isseroff RR (2005) Di-rhamnolipid from Pseudomonas aeruginosa displays differential effects on human keratinocyte and fibroblast cultures. J Dermatol Sci 40:141–143
Piljac G, Piljac V (1995a) Pharmaceutical preparation based on rhamnolipid. US Patent No. 5,466,675
Piljac G, Piljac V (1995b) Immunological activity of rhamnolipids. US Patent No. 5,466,675
Stipcevic T, Piljac A, Piljac G (2006) Enhanced healing of full-thickness burn wounds using di-rhamnolipid. Burns 32:24–34
Stipcevic T, Piljac T, Piljac J, Dujmic T, Piljac G (2006b) Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration. US Patent No. 7,129,218
Piljac A, Stipcević T, Piljac-Zegarac J, Piljac G (2008) Successful treatment of chronic decubitus ulcer with 0.1 % dirhamnolipid ointment. J Cutan Med Surg 12:142–146
Hitoshi S, Kippin T, van der Kooy D (2011) Culturing adult neural stem cells: application to the study of neurodegenerative and neuropsychiatric pathology. In: Seki T, Sawamoto K, Parent JM, Alvarez-Buylla A (eds) Neurogenesis in the adult brain II. Springer, Tokyo (JP), pp 189–207
Kippin TE, Kapur S, van der Kooy D (2005) Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. J Neurosci 25:5815–5823
Kippin TE, Martens DJ, van der Kooy D (2005) p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 19:756–767
Venerando B, Roberti S, Sonnino S, Fiorilli A, Tettamanti G (1982) Interactions of ganglioside GM1 with human and fetal calf sera formation of ganglioside-serum albumin complexes. Biochim Biophys Acta 692:18–26
Schengrund CL, Mummert CM (1998) Exogenous gangliosides. How do they cross the blood-brain and how do they inhibit cell proliferation. Ann N Y Acad Sci 845:278–284
Hakomori SI (2002) The glycosynapse. Proc Natl Acad Sci USA 99:225–232
Yanagisawa M, Yu RK (2009) The expression of glycoconjugates in neural stem cells. J Lipid Res 50:440–445
Iwabuchi K, Nakayama H, Iwahara C, Takamori K (2010) Significance of glycosphingolipid fatty acid chain length on membrane microdomain-mediated signal transduction. FEBS Lett 584:1642–1652
Mutoh T, Yano S, Yamamoto H (2004) Signal transduction mechanisms for the survival and death of neurons and muscle cells: modulation by membrane lipid rafts and their abnormality in the disorders of the nervous system. Nihon Shinkei Seishin Yakurigaku Zasshi 24:199–203
Cabrera-Poch N, Sánchez-Ruiloba L, Rodriguez-Martinez M, Iglesias T (2004) Lipid raft disruption triggers protein kinase C and Src-dependent protein kinase D activation and Kidins220 phosphorylation in neuronal cells. J Biol Chem 279:28592–28602
Evans SV, MacKenzie CR (1999) Characterization of protein-glycolipid recognition at the membrane bilayer. J Mol Recognit 12:155–168
Young SZ, Taylor MM, Bordey A (2011) Neurotransmitters couple brain activity to subventricular zone neurogenesis. Eur J Neurosci 33:1123–1132
Bieberich E (2012) It’s a lipid’s world: bioactive lipid metabolism and signalling in neural stem cell differentiation. Neurochem Res 37:1208–1229
Seren S, Rubini R, Lazzaro A, Zanoni R, Fiori MG, Leon A (1990) Protective effects of a monosialoganglioside derivative following transitory forebrain ischemia in rats. Stroke 21:1607–1612
Figliomeni B, Bacci B, Panozzo C, Fogarolo F, Triban C, Fiori MG (1992) Experimental diabetic neuropathy: effect of ganglioside treatment on axonal transport of cytoskeletal proteins. Diabetes 41:866–871
Masuda Y, Sugiyama T (2000) The effect of globopentaosylceramide on a depression model, mouse forced swimming. Tohoku J Exp Med 191:47–54
Schneider JS, Sendek S, Daskalakis C, Cambi F (2010) GM1 ganglioside in Parkinson’s disease: results of a five year open study. J Neurol Sci 292:45–51
Stessin AM, Gursel DB, Schwartz A, Parashar B, Kulidzhanov FG, Sabbas AM, Boockvar J, Nori D, Wernicke AG (2012) FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells. Neurosci Lett 516:253–258
Acknowledgments
This work was supported by National Institute on Drug Abuse grant DA027115. Paradigm Biomedical Inc. NY, USA is the owner of patents on rhamnolipids.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stipcevic, T., Knight, C.P. & Kippin, T.E. Stimulation of adult neural stem cells with a novel glycolipid biosurfactant. Acta Neurol Belg 113, 501–506 (2013). https://doi.org/10.1007/s13760-013-0232-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-013-0232-4